Noninvasive molecular subtyping of pediatric low-grade glioma with self-supervised transfer learning - Tak, Divyanshu; Ye, Zezhong; Zapaischykova, Anna; Zha, Yining; Boyd, Aidan; Vajapeyam, Sridhar; Chopra, Rishi; Hayat, Hasaan; Prabhu, Sanjay; Liu, Kevin X.; Elhalawani, Hesham; Nabavidazeh, Ali; et al. (medRxiv, 2023)
Purpose To develop and externally validate a scan-to-prediction deep-learning pipeline for noninvasive, MRI-based BRAF mutational status classification for pLGG.Materials and Methods We conducted a retrospective study of two pLGG datasets with linked genomic and diagnostic T2-weighted MRI of patients: BCH (development dataset, n=214 [60 (28%) BRAF fusion, 50 (23%) BRAF V600E, 104 (49%) wild-type), and Child Brain Tumor Network (CBTN) (external validation, n=112 [60 (53%) BRAF-Fusion, 17 (15%) BRAF-V600E, 35 (32%) wild-type]). We developed a deep learning pipeline to classify BRAF mutational status (V600E vs. fusion vs. wild-type) via a two-stage process: 1) 3D tumor segmentation and extraction of axial tumor images, and 2) slice-wise, deep learning-based classification of mutational status. We investigated knowledge-transfer and self-supervised approaches to prevent model overfitting with a primary endpoint of the area under the receiver operating characteristic curve (AUC). To enhance model interpretability, we developed a novel metric, COMDist, that quantifies the accuracy of model attention around the tumor.Results A combination of transfer learning from a pretrained medical imaging-specific network and self-supervised label cross-training (TransferX) coupled with consensus logic yielded the highest macro-average AUC (0.82 [95% CI: 0.70-0.90]) and accuracy (77%) on internal validation, with an AUC improvement of +17.7% and a COMDist improvement of +6.4% versus training from scratch. On external validation, the TransferX model yielded AUC (0.73 [95% CI 0.68-0.88]) and accuracy (75%).Conclusion Transfer learning and self-supervised cross-training improved classification performance and generalizability for noninvasive pLGG mutational status prediction in a limited data scenario.Summary Statement The authors developed and externally validated an automated, scan-to-prediction deep learning pipeline that classifies BRAF Mutational status in pediatric low-grade gliomas from T2-Weighted MRI scans.An innovative training approach combining self-supervision and transfer learning (“TransferX”) is developed to boost model performance in a low data setting;TransferX enables the development of a scan-to-prediction pipeline for pediatric LGG mutational status (BRAF V600E, fusion, or wildtype) with ≥75% accuracy on internal and external validation;An evaluation metric, “COMDist”, is introduced to increase interpretability and quantify the accuracy of the model’s attention around the tumor.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported in part by the National Institutes of Health (NIH) (U24CA194354, U01CA190234, U01CA209414, R35CA22052, and K08DE030216), the National Cancer Institute (NCI) Spore grant (2P50CA165962), the European Union - European Research Council (866504), the Radiological Society of North America (RSCH2017), the Pediatric Low-Grade Astrocytoma Program at Pediatric Brain Tumor Foundation, and the William M. Wood Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with the Declaration of Helsinki guidelines and following the approval of the Dana-Farber/Boston Children’s/Harvard Cancer Center Institutional Review Board (IRB). Waiver of consent was obtained from IRB prior to research initiation due to public datasets or retrospective study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://github.com/DivyanshuTak/BRAF_Classification pLGGpediatric low-grade gliomaT2WT2 WeightedCNNConvolutional neural networkSDStandard DeviationCIConfidence IntervalAUCArea under the curveCBTNChild brain tumor network.